Table 3.

Examples of FDA-approved novel therapeutics in colorectal cancer.

No	Drug name	Trade name	Properties	Disease	Date of approval	Ref.
Chemotherapy
1	Irinotecan HCl	Camptosar	DNA topoisomerase I inhibitor	Metastatic colorectal cancer	06/14/1996	(138)
2	Oxaliplatin	Eloxatin	Organoplatinum alkylating agent	Colorectal cancer (in combination with leucovorin and 5-FU)	08/09/2002	(139)
Passive immunotherapy (Ab based)
3	Cetuximab	Erbitux	EGFR-directed mAb	Colorectal cancer	02/12/2004	(140, 141)
4	Bevacizumab	Avastin	VEGF-A-directed mAb	Colorectal cancer	02/26/2004	(142)
5	Panitumumab	Vectibix	EGFR-directed mAb	Colorectal cancer	09/27/2006	(143, 144)
6	Pembrolizumab	Keytruda	PD-1 targeted Ab	Colorectal cancer (for (dMMR and MSI-H types)	23/05/2017	(145, 146)
7	Nivolumab	Opdivo	PD-1 targeted Ab	Colorectal cancer (for (dMMR and MSI-H types)	01/08/2017	(147)
8	Yervoy	Ipilimumab	CTLA-4 targeted Ab	Colorectal cancer (for (dMMR and MSI-H types)	10/07/2018	(148–150)